Why more doctors are treating children and adolescents with weight loss drugs

The Pediatric GLP-1 Conversation: PBS NewsHour's Take

PBS NewsHour takes on one of the most sensitive topics in the GLP-1 debate: should these drugs be used in children and adolescents? The segment approaches the question with the journalistic balance that PBS is known for, interviewing pediatric endocrinologists, parents, and policy experts to present a multi-sided view. The result is a thoughtful exploration of a topic that generates strong opinions on all sides.

The segment opens with the reality that childhood obesity has reached levels that many pediatricians consider a crisis. The CDC data shows that nearly 20% of American children and adolescents have obesity, and the rates have been climbing for decades. For the most severely affected kids, obesity is more than a weight issue. It comes with type 2 diabetes (once called "adult-onset" because it was essentially unheard of in children), fatty liver disease, sleep apnea, joint problems, and significant mental health consequences including depression, anxiety, and social isolation. The pediatricians interviewed argue that for these kids, the risks of untreated severe obesity outweigh the theoretical risks of medication.

The counter-argument, also represented in the segment, comes from professionals who worry about using potent medications in developing bodies. Children's brains, bones, hormonal systems, and growth plates are still maturing. GLP-1 medications have been studied primarily in adults, and while the adolescent trials that have been completed show promising results, the long-term effects on growth, development, and reproductive health are genuinely unknown. Some experts argue that we should exhaust behavioral and dietary interventions before turning to medication, and that prescribing these drugs to children normalizes a pharmaceutical approach to a problem that has environmental and societal roots.

What the Pediatric Clinical Trials Actually Show

The segment references the STEP TEENS trial, which studied semaglutide in adolescents aged 12-17. The results were striking: participants receiving semaglutide lost an average of about 16% of their body weight, compared to slight weight gain in the placebo group. Many participants saw their BMI drop below the obesity threshold. The side effect profile was similar to what is seen in adults, with GI symptoms being the most common. No unexpected safety signals specific to the adolescent population were identified during the trial period.

One of the experts interviewed notes that the magnitude of effect in the adolescent trial was actually larger than in adult trials, which may reflect the greater physiological responsiveness of younger bodies. The clinical significance of this is substantial because adolescents who can achieve healthy weight before adulthood may avoid the cascading metabolic consequences that accumulate over decades of living with obesity.

The segment is transparent about the limitations of the data. The STEP TEENS trial followed participants for 68 weeks, which provides short to medium term safety and efficacy data. But children who start on GLP-1 medications may need to take them for years, potentially into adulthood. The effects of that kind of extended exposure during critical developmental periods are not yet known. The experts on both sides of the debate acknowledge this gap honestly, which is one of the segment's strengths.

The Parent and Patient Perspective

The segment includes interviews with parents of adolescents who have been treated with GLP-1 medications. Their stories add emotional weight to the clinical data. One parent describes watching their child be bullied relentlessly due to weight, developing depression, and withdrawing from activities they once enjoyed. After starting treatment, the weight loss was accompanied by dramatic improvements in mood, confidence, and social engagement. For this family, the medication was more than about the number on the scale; it was about their child's quality of life and mental health.

Another parent expresses the anxiety of putting their teenager on a relatively new medication. They worry about unknown long-term effects, about dependency, and about the message it sends about body image and pharmaceutical solutions. Their perspective is valid and represents what many parents feel when confronted with this decision. The segment does not dismiss either perspective, which reflects the genuine difficulty of these choices.

The segment also features a brief interview with an adolescent patient who describes what the experience has been like. Their account of reduced food preoccupation and increased ability to participate in physical activities provides a first-person view that clinical data alone cannot capture. The patient is articulate about both the benefits and the inconvenience of weekly injections, and their perspective is presented without editorializing.

What the Segment Gets Right and Where It Could Go Further

PBS NewsHour does an excellent job presenting multiple perspectives without false equivalence. The pediatric endocrinologists who support GLP-1 use in appropriate adolescent patients are given space to explain their evidence-based rationale. The skeptics are given space to raise legitimate concerns. Neither side is portrayed as unreasonable. This balanced approach respects the intelligence of the viewer and avoids the sensationalism that some media outlets bring to this topic.

Where the segment could go further is in discussing the practical barriers to pediatric GLP-1 access. Insurance coverage for weight-loss medications in children is even more inconsistent than for adults. The cost of brand-name GLP-1s is beyond what most families can afford out of pocket. And the question of whether pediatricians should be the ones prescribing these drugs, or whether treatment should be managed by pediatric endocrinologists or obesity medicine specialists, is an access issue in itself since these specialists are concentrated in urban areas and academic medical centers. A child in rural Mississippi may have very different access than a child in Boston.

The segment raises but does not fully explore the question of long-term developmental effects. Adolescents are not small adults. Their bodies are undergoing rapid changes in hormonal regulation, brain development, bone mineralization, and organ maturation. GLP-1 medications interact with several of these developmental processes in ways that are not fully understood. The GLP-1 receptor is expressed in the brain, including regions involved in emotional regulation and cognitive function that are actively developing during adolescence. Whether chronic GLP-1 receptor agonism during this critical developmental period has long-term neurological effects, positive, negative, or neutral, is a question that cannot be answered by a 68-week trial. It requires years of post-marketing surveillance and longitudinal follow-up studies.

The psychosocial context of prescribing weight-loss medication to adolescents also deserves more attention than the segment provides. Teenagers are developing their identity, their relationship with food, and their body image during a period of intense social pressure. Introducing a medication that dramatically alters appetite and body weight adds another variable to an already complex developmental equation. Some adolescents may internalize the medication as confirmation that something is "wrong" with them. Others may develop unhealthy psychological dependence on the drug's appetite-suppressing effects. These risks do not necessarily outweigh the benefits for adolescents with severe obesity, but they underscore the importance of psychological support as a standard part of any pediatric GLP-1 treatment protocol, not an optional add-on.

Access disparities in pediatric obesity treatment are particularly stark. The pediatric endocrinologists and obesity specialists who are most qualified to prescribe and manage GLP-1 therapy in adolescents are concentrated in academic medical centers in major cities. Families in rural areas, small towns, and underserved communities often have to travel hours to access specialist care, which creates barriers that disproportionately affect the populations with the highest obesity rates. Telemedicine has partially bridged this gap, but prescribing controlled medications for minors via telemedicine raises its own regulatory and clinical challenges. Addressing these access disparities requires systemic solutions, more than better drugs.

Questions for Parents Considering This Path

If you are a parent weighing whether a GLP-1 medication might be appropriate for your child, bring these questions to your pediatrician or specialist. What is my child's specific clinical picture, and does it meet the criteria for medication beyond lifestyle intervention? What does the current evidence say about long-term safety in adolescents for the specific drug being considered? What monitoring plan would be in place to track growth, development, and any side effects? What happens if we need to stop the medication, and what is the plan for preventing weight regain? Is there a multidisciplinary team (nutritionist, behavioral health, exercise specialist) that should be involved alongside the medication?

The question of whether GLP-1 medications for adolescents should require specialist prescribing or whether primary care pediatricians should be able to initiate therapy is an active debate in the field. Restricting prescribing to specialists ensures more experienced management but limits access, especially in underserved areas. Allowing primary care prescribing expands access but raises concerns about adequate monitoring and dose management in less experienced hands. The emerging consensus seems to be moving toward a shared-care model where specialists initiate therapy and establish the treatment plan, then primary care providers manage ongoing prescriptions and routine monitoring, with specialist re-evaluation at defined intervals or when complications arise. This model balances expertise with access and mirrors how other complex pediatric conditions are managed across the healthcare system.

Who Should Watch This

This segment is a must-watch for any parent whose child is struggling with obesity, whether you are considering medication or not. The overview of the clinical data, the parent perspectives, and the expert debate will help you have a more informed conversation with your child's healthcare team. It is also valuable for pediatricians and family medicine providers who are increasingly being asked about GLP-1s for adolescent patients. For the general public, this is an important piece of health journalism on a topic that affects millions of families and will only become more prominent as these medications become more established in pediatric practice.